Ansa Biotechnologies, Inc.’s Post

🚀 Cyclodextrins: New Horizons in Gene Delivery 🧬 In gene therapy, safety and efficiency are paramount. Cyclodextrins, cyclic oligosaccharides derived from starch, are emerging as promising non-viral nanocarriers for genetic material. 🔬 Key Benefits: Biocompatibility: Low toxicity, minimal adverse reactions. Versatility: Efficiently carries DNA, RNA, and siRNA. Controlled Release: Ensures targeted, prolonged therapeutic effects. 🚧 Challenges: Improving transfection efficiency and in vivo performance remains a focus. 🔍 GENEGUT Project: Our Horizon 2020 grant project aims to develop tools for delivering oligonucleotides to treat Crohn's disease. Cyclodextrins offer a safer, versatile alternative to viral vectors, potentially revolutionizing gene therapy. #GeneTherapy #Cyclodextrins #Biotech #Healthcare #GENEGUT

🔬 Research Alert! published in #DrugDevIndPharm 2022, VOL. 48, NO. 1, 1–11 🌟 A cationic cyclodextrin derivative-lipid hybrid nanoparticles for gene delivery effectively promotes stability and transfection efficiency 🌟 This research article explores the development of a novel gene delivery system using lipid-polymer hybrid nanoparticles (LHNPs) composed of α-cyclodextrin-conjugated generation-2 polyamidoamine dendrimers (CDG2) and lipids. The study demonstrates that these CDG2-LHNPs exhibit superior stability and transfection efficiency compared to traditional liposomes and polymers. The nanoparticles were stable for up to 15 days at various temperatures and showed high transfection efficiency mediated by multiple endocytosis pathways, particularly caveolae-mediated endocytosis, which helps avoid lysosomal degradation. The hybrid system's enhanced cell uptake and proton buffering capacity contribute to its effectiveness, making it a promising candidate for gene therapy applications. 📖 Read the full article here: https://lnkd.in/gcxwaYrs #GeneTherapy #Nanoparticles #DrugDelivery

The surge in groundbreaking research and medical advancements is propelling the cell and gene therapy sector to unprecedented heights. Some examples include Synthetic biology, In vivo CAR-T cell engineering, iPSC-derived therapies, and many more. Want to see the complete list? Our whitepaper spotlights emerging cell and gene therapy technologies that can shape the biotech industry for the next decade. Dive in to learn about the challenges and opportunities that lie ahead. https://lnkd.in/eiAu9rjD

The Gene light switch Today's gene therapy faces a critical challenge: traditional methods introduce foreign proteins to regulate genes, often provoking detrimental immune responses as the body combats these alien elements. Addressing this, Baylor College of Medicine researchers, led by Dr. Laising Yen, have developed an innovative RNA-based technology. Their method employs small, FDA-approved molecules to interact with RNA, avoiding immune activation. This 'light switch' for genes, adjustable with common drugs like tetracycline, promises precise control within safe drug concentrations. This breakthrough, a decade in the making and published in Nature Biotechnology, has potential applications in various conditions, including genetic disorders and cancer, offering a more targeted and safer approach to gene therapy. Amit Saxena Ajay Nandgaonkar Sanju Senthil Kumar Suchitaa Paatil Dr Taruna Anand #accessAIchemy #access #genetherapy read more :https://lnkd.in/ggbJ_DAm

📢 Interested in streamlining viral gene therapy workflows? Check out this informative article from FUJIFILM Diosynth Biotechnologies on utilizing multiplex ddPCR: https://ow.ly/C1KX50PWxLK Learn how the use of multiplex ddPCR technology can significantly improve the efficiency of viral gene therapy processes. This innovative approach detailed in the article offers valuable insights for biotech professionals seeking to enhance their workflows and advance the field. Don't miss out on this opportunity to stay at the forefront of biotechnology. #Science #Biotech #Advancements #biotechnology #innovation

Don't forget to join us today at 3pm GMT / 4pm CET /10am EST for the first webinar in our 3 part series on CRISPR and Gene Editing ONLINE. If you can't make it you can still register to catch up on-demand: https://lnkd.in/dA9KycdX   Today, we'll be discussing advances in gene editing systems. We'll be highlighting their applications and benefits and discussing the future of gene editing technologies, both from a technological standpoint and in relation to future therapeutics. Talk 1: Precise Transcript Targeting by CRISPR-Csm Complexes David Colognori, Post-Doctoral Associate, Doudna Lab, UC Berkeley    Talk 2: PRCISR CRISPR: Vivlion’s CRISPR-enabled PCR-free discovery platform   Martin Wegner, Head of R&D, Vivlion GmbH    Talk 3: Precise and Versatile Genome Engineering with Prime Editing  Andrew Anzalone, Head of the Prime Editing Platform and Scientific Co-Founder, Prime Medicine, Inc. #CRISPR #geneediting

🤔 What are the main features of Lipid Nanoparticles (LNPs), the most promising nanoformulations in the clinic? And why have they surpassed liposomes? Our latest blog dives into their unique structures, efficiencies, and versatile applications. Discover how DIVERSA's innovation is contributing to the field and the development of advanced gene therapies with complex molecules such as mRNAs. Check out the blog for a detailed comparison and insights into current lipid nanocarriers for gene delivery. 👇🏼 https://lnkd.in/gduh3fx8 Biocat, BioRegion of Catalonia CELTA INGENIEROS SL Labclinics, S.A LubioScience PROGEN Tebubio ZAGENO Inc. #drugdelivery #nanoparticle #deliveryvehicles #nanotechnology #nanomedicine #liposomes #lipidnanoparticles